Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is:
- To evaluate liothyronine (Cytomel) as an accelerating agent (i.e. faster rate to
clinical remission) to electroconvulsive therapy.
- To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side
effect of ECT treatment.
- To evaluate whether thyroid status at the time of remission is associated with
subsequent relapse rate.
- To evaluate genetic polymorphisms in enzymes responsible for thyroid metabolism and the
serotonin transporter promoter gene in depression (5-HTTLRP).